Development and Challenges of Synthetic Retinoid Formulations in Cancer

被引：10

作者：

Assi, Sara ^{[1
]}

El Hajj, Hiba ^{[2
]}

Hayar, Berthe ^{[3
]}

Pisano, Claudio ^{[4
]}

Saad, Walid ^{[5
]}

Darwiche, Nadine ^{[3
]}

机构：

[1] Amer Univ Beirut, Maroun Semaan Fac Engn & Architecture, Dept Biomed Engn, Beirut, Lebanon

[2] Amer Univ Beirut, Fac Med, Dept Expt Pathol Immunol & Microbiol, Beirut, Lebanon

[3] Amer Univ Beirut, Fac Med, Dept Biochem & Mol Genet, POB 11-0236, Beirut 11072020, Lebanon

[4] Inst Mol Biol & Genet, Biogem, Via Camporeale, I-83031 Ariano Irpino, AV, Italy

[5] Amer Univ Beirut, Maroun Semaan Fac Engn & Architecture, Dept Chem Engn, POB 11-0236, Beirut 11072020, Lebanon

来源：

CURRENT DRUG DELIVERY | 2023年 / 20卷 / 09期

关键词：

Synthetic retinoid; delivery system; formulation; development; drug; cancer; MYELOID-LEUKEMIA CELLS; ACUTE PROMYELOCYTIC LEUKEMIA; RECEPTOR AGONIST BEXAROTENE; X-RECEPTOR; ANTITUMOR-ACTIVITY; PLGA MICROSPHERES; SOLID DISPERSIONS; RESISTANT NEUROBLASTOMA; THERAPEUTIC-EFFICACY; SURFACE MODIFICATION;

D O I：

10.2174/1567201819666220810094708

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Retinoids represent a class of chemical compounds derived from or structurally and functionally related to vitamin A. Retinoids play crucial roles in regulating a range of crucial biological processes spanning embryonic development to adult life. These include regulation of cell proliferation, differentiation, and cell death. Due to their promising characteristics, retinoids emerged as potent anti-cancer agents, and their effects were validated in vitro and in vivo preclinical models of several solid and hematological malignancies. However, their clinical translation remained limited due to poor water solubility, photosensitivity, short half-life, and toxicity. The development of retinoid delivery formulations was extensively studied to overcome these limitations. This review will summarize some preclinical and commercial synthetic retinoids in cancer and discuss their different delivery systems.

引用

页码：1314 / 1326

页数：13

共 127 条

[91] Preventive and Therapeutic Effects of the Retinoid X Receptor Agonist Bexarotene on Tumors [J].

Qi, Lisi ;

Guo, Yuanyuan ;

Zhang, Pei ;

Cao, Xiaorong ;

Luan, Yuxia .

CURRENT DRUG METABOLISM, 2016, 17 (02) :118-128

[92] Folate-modified bexarotene-loaded bovine serum albumin nanoparticles as a promising tumor-targeting delivery system [J].

Qi, Lisi ;

Guo, Yuanyuan ;

Luan, Jingjing ;

Zhang, Dianrui ;

Zhao, Zhongxi ;

Luan, Yuxia .

JOURNAL OF MATERIALS CHEMISTRY B, 2014, 2 (47) :8361-8371

[93] Development and validation of a liquid chromatography-tandem mass spectrometry method for the determination of ST1926, a novel oral antitumor agent, adamantyl retinoid derivative, in plasma of patients in a Phase I study [J].

Sala, Federica ;

Zucchetti, Massimo ;

Bagnati, Renzo ;

D'Incalci, Maurizio ;

Pace, Silvia ;

Capocasa, Francesca ;

Marangon, Elena .

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2009, 877 (27) :3118-3126

[94] Microemulsion for Prolonged Release of Fenretinide in the Mammary Tissue and Prevention of Breast Cancer Development [J].

Salata, Giovanna Cassone ;

Malago, Isabella D. ;

Carvalho Dartora, Vanessa F. M. ;

Marcal Pessoa, Ana Flavia ;

de Abreu Fantini, Marcia Carvalho ;

Costa, Soraia K. P. ;

Machado-Neto, Joao Agostinho ;

Lopes, Luciana B. .

MOLECULAR PHARMACEUTICS, 2021, 18 (09) :3401-3417

[95] Unlocking the potential of retinoic acid in anticancer therapy [J].

Schenk, T. ;

Stengel, S. ;

Zelent, A. .

BRITISH JOURNAL OF CANCER, 2014, 111 (11) :2039-2045

[96]

Simon AM, 2012, MED CHEM, V8, P805

[97] Cytotoxicity and molecular activity of fenretinide and metabolites in T-cell lymphoid malignancy, neuroblastoma, and ovarian cancer cell lines in physiological hypoxia [J].

Song, Michael M. ;

Makena, Monish R. ;

Hindle, Ashly ;

Koneru, Balakrishna ;

Thinh H Nguyen ;

Verlekar, Dattesh U. ;

Cho, Hwangeui ;

Maurer, Barry J. ;

Kang, Min H. ;

Reynolds, C. Patrick .

ANTI-CANCER DRUGS, 2019, 30 (02) :117-127

[98] Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: Screening in an infectious disease model [J].

Suarez, S ;

O'Hara, P ;

Kazantseva, M ;

Newcomer, CE ;

Hopfer, R ;

McMurray, DN ;

Hickey, AJ .

PHARMACEUTICAL RESEARCH, 2001, 18 (09) :1315-1319

[99] PEGylation as a strategy for improving nanoparticle-based drug and gene delivery [J].

Suk, Jung Soo ;

Xu, Qingguo ;

Kim, Namho ;

Hanes, Justin ;

Ensign, Laura M. .

ADVANCED DRUG DELIVERY REVIEWS, 2016, 99 :28-51

[100] Enhanced antitumor efficacy of vitamin E TPGS-emulsified PLGA nanoparticles for delivery of paclitaxel [J].

Sun, Yanbin ;

Yu, Bo ;

Wang, Guoying ;

Wu, Yongsheng ;

Zhang, Xiaomin ;

Chen, Yanmin ;

Tang, Suoqing ;

Yuan, Yuan ;

Lee, Robert J. ;

Teng, Lesheng ;

Xu, Shun .

COLLOIDS AND SURFACES B-BIOINTERFACES, 2014, 123 :716-723

← 4 5 6 7 8 9 10 11 12 13 →